Head-to-head evidence
Desidustat vs Vadadustat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Desidustat · Oxemia
Marketed by Zydus Lifesciences
NCT04012957 · Phase 3 · completed
The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Vadadustat · Vafseo
Marketed by Akebia Therapeutics
NCT02648347 · Phase 3 · completed
Participants were randomized to vadadustat or active treatment with darbepoetin alfa, but the trial was open-label; 879 received vadadustat and 872 received darbepoetin alfa. The hemoglobin primary endpoint met the prespecified non-inferiority criterion, while the primary cardiovascular safety comparison did not, making the findings mixed rather than clearly positive.
Next expected readout: April 2027 · NCT07565701 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · Vadadustat's landscape